New Model Predicts Liraglutide's Effects by Tracking Target Engagement in Rats

Liraglutide, a GLP-1 receptor agonist, is a cornerstone treatment for type 2 diabetes and obesity. Its effectiveness is tied to how it interacts with its target receptors, a process often complicated by target-mediated drug disposition (TMDD), where the drug's binding to its target influences its own clearance. A deeper understanding of how this target engagement dictates liraglutide's pharmacodynamic (drug effect) profile is essential for optimizing therapeutic strategies.

The developed TMDD model accurately captured the non-linear pharmacokinetics of liraglutide in rats, demonstrating that receptor binding significantly influences drug clearance, particularly at lower doses. They observed a clear dose-dependent reduction in plasma glucose levels, with the 1 mg/kg dose achieving a 45% decrease from baseline glucose at 24 hours post-administration, significantly outperforming the 15% decrease seen with 0.1 mg/kg. > The model predicted that 90% of GLP-1 receptors were engaged at the 1 mg/kg dose, establishing a strong correlation between target saturation and maximal glucose-lowering effects. Incorporating TMDD into the model improved the prediction accuracy of liraglutide's glucose-lowering effects by 2.3-fold compared to traditional PK/PD models, reducing prediction error from 25% to 11%. Furthermore, the estimated dissociation constant (Kd) for liraglirude's binding to the GLP-1 receptor was approximately 0.5 nM, indicating high-affinity binding.